Pharmicell Co Ltd

005690

Company Profile

  • Business description

    Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

  • Contact

    12F Chungho B/D
    3-2 Nonhyun-dong Gangnam-gu
    Seoul135-010
    KOR

    T: +82 234960114

    http://www.pharmicell.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    134

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,467.004.400.05%
CAC 407,856.28112.531.45%
DAX 4023,568.3969.070.29%
Dow JONES (US)41,249.38119.07-0.29%
FTSE 1008,601.0946.290.54%
HKSE23,549.46681.722.98%
NASDAQ17,928.920.780.00%
Nikkei 22537,644.26140.930.38%
NZX 50 Index12,676.7571.680.57%
S&P 5005,659.910.000.00%
S&P/ASX 2008,233.502.300.03%
SSE Composite Index3,369.2427.250.82%

Market Movers